Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Trial sponsor
Hoffmann-La Roche
Scientific Title
A phase III, double-blind, placebo-controlled, randomised study of taselisib plus Fulvestrant versus placeo plus Fulvestrant in postmenopausal women with oestrogen receptor-positive and HER2-negative locally advanced or metastatic breast cancer who have disease recurrence or progression during or after aromatase inhibitor therapy.